SpringWorks Therapeutics (SWTX) Scheduled to Post Earnings on Tuesday

SpringWorks Therapeutics (NASDAQ:SWTX) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect SpringWorks Therapeutics to post earnings of ($0.76) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million for the quarter, compared to the consensus estimate of $34.42 million. The company’s revenue was up 59732900.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.25) EPS. On average, analysts expect SpringWorks Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $30.94 on Tuesday. SpringWorks Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $53.92. The business has a 50-day simple moving average of $33.92 and a two-hundred day simple moving average of $37.67.

Wall Street Analyst Weigh In

SWTX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Wedbush reissued an “outperform” rating and issued a $77.00 price target (up from $75.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Finally, HC Wainwright restated a “buy” rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of “Buy” and an average price target of $68.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.